GSK is pumping £50 million (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge ...

Last week, the outgoing leader of the FDA’s devices center, long-time chief Jeff Shuren, M.D., endorsed acting head Michelle ...

The R&D software developer Dotmatics is rolling out a platform for discovering and developing therapeutic antibodies and ...

The biotech engaged with the FDA on alternative pathways to approval after seeing safety and efficacy data from the phase 1/2 ...

China-based Minghui Pharmaceutical has linked its thyroid eye disease treatment to a reduction in eye bulging in a small ...

The FDA has granted a de novo clearance to a new type of stent designed to hold open the passages down the windpipe and into ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by demonstrating in an interim ...

AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

Editas Medicines has signed a $238 million biobucks pact to combine Genevant Science’s lipid nanoparticle (LNP) tech with the ...

Horizon Surgical Systems, a startup developing automated, artificial intelligence-powered robotic tools for eye surgery, has ...